Study/Projects - Microbiome

Vaginal Microbiota in HIV Infected and Uninfected Pregnant Women (Stand Alone)

Post Date: 
2018-10-16
   |   
Countries: 
   |   
Clinical Sites: 
Amita Gupta, MD, MHS, and Shilpa Naik, MD, are PIs for this study; Rupak Shivakoti, PhD, MSPH, is Co-Investigator The makeup of vaginal microbiota is dynamic and may play a role in the birth outcomes of pregnant women. While HIV and pregnancy both uniquely impact vaginal microbiota, the impact of...

Gut Microbiota of HIV Infected Pregnant Women

Post Date: 
2018-06-14
   |   
Countries: 
   |   
Clinical Sites: 
Birth Outcomes in HIV Both antiretroviral-therapy (ART)-naïve and ART-experienced HIV-infected pregnant women have higher incidences of pre-term birth (PTB) compared to HIV-uninfected women. For example, the global prevalence of PTB is around 8%, while the rates in in HIV-infected populations are...

TB and Pregnancy Impact of Immune Changes of HIV and Stages of Pregnancy on Tuberculosis: Nested Study on Temporal Dynamics of Gut Microbiota in HIV Infected Pregnant Women

Post Date: 
2016-07-05
   |   
Countries: 
   |   
Clinical Sites: 
This is a nested prospective longitudinal cohort study of 35 HIV-infected and 35 HIV-noninfected pregnant women who are part of the parent study “Impact of Immune Changes of HIV and Stages of Pregnancy on Tuberculosis." The objectives are to: Determine the association of gestational age with...

Inflammation in HIV-infected Pregnant Women: Relationship with Diet, Gut Microbiome and Preterm Birth

Post Date: 
2014-10-28
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated May 7, 2018. P regnancy is a state of relative immunosuppression in order to protect the fetus from being rejected. It has also been shown that the Th-1 helper cell response, which is normally necessary for overcoming TB infection, is suppressed in pregnancy. Thus,...

Impact of Malnutrition on HIV Treatment Failure in Resource-limited Settings

Post Date: 
2009-04-02
   |   
Countries: 
   |   
Clinical Sites: 
This study, NWCS 319, was terminated August 20, 2019. Highly active antiretroviral therapy (HAART) has reduced morbidity and mortality among HIV-infected persons worldwide. However, early treatment failure (i.e. WHO stage 3 or 4 illnesses or death during the first 24 months of HAART) is more than 3...